This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Mantle cell lymphoma (MCL)

Unknown

Mouse studies suggest Revlimid lenalidomide helps treat MCL by inhibiting lymphangiogenesis. In mouse xenograft models of MCL, Revlimid inhibited tumor growth and decreased lymphangiogenesis, the number of tumor-associated macrophages and cancer dissemination to auxiliary lymph nodes compared with vehicle. Next steps could include validating the mechanism in additional animal models and exploring other methods of disrupting lymphangiogenesis to treat MCL.
Celgene Corp.'s Revlimid is approved to treat MCL, multiple myeloma (MM) and myelodysplastic syndrome (MDS).

SciBX 6(47); doi:10.1038/scibx.2013.1344
Published online Dec. 12, 2013

Patent and licensing status unavailable

Song, K. et al. Cancer Res.; published online Oct. 24, 2013;
doi:10.1158/0008-5472.CAN-13-0750
Contact: Lijun Xia, Oklahoma Medical Research Foundation, Oklahoma City, Okla.
e-mail:
lijun-xia@omrf.org